Novartis (NYSE: NVS) Navigates Clinical Setbacks and Stock Rating Adjustment

• Novartis (NYSE: NVS), a leading global healthcare company, is facing significant challenges due to recent clinical trial failures impacting its drug pipeline.
• Investment firm HSBC upgraded its rating for Novartis stock to "Hold," suggesting that recent negative news might already be factored into the stock's current valuation.
• Failures of key investigational drugs, del-desiran and pelacarsen, have contributed to a 14% decline in Novartis shares and raised concerns about the company's research productivity.

Novartis (NYSE: NVS) is a global healthcare company based in Switzerland that researches, develops, and manufactures a wide range of medicines. With a market capitalization of approximately $261.31 billion, it is a major player in the pharmaceutical industry. The company faces competition from other large pharmaceutical firms like Amgen (NASDAQ: AMGN).

On September 10, 2026, the investment firm HSBC upgraded its rating for Novartis from "Reduce" to "Hold." A "Hold" rating suggests that the firm expects the stock to perform in line with the broader market. The stock was trading at $137.48 when the new rating was issued.

This rating change comes after a period of significant challenges for the company. Novartis recently announced that its investigational drug, del-desiran, failed its late-stage study, as highlighted by Zacks Investment Research. This news, marking the second pipeline setback in five days, contributed to a sharp decline in the company's stock price.

Further pressure on the stock comes from other clinical trial failures. The company's cholesterol drug, pelacarsen, also failed to meet its primary goals in a major trial involving over 8,000 patients. These developments have caused Novartis shares to fall by 14% and have raised concerns about the company's research productivity.

The stock's recent price movement reflects these setbacks. Novartis has traded as high as $170.46 over the past year, but recent events have pushed the price down. The current price of $137.48 may reflect that much of this negative news is now factored into the stock's valuation by the market.